Skip to main content
Premium Trial:

Request an Annual Quote

Oncimmune Gets Medicare Reimbursement for Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer detection company Oncimmune today said that it has received Medicare coverage for a new blood-based test that it claims can detect cancers as much as five year earlier than current testing methods.

The test is based on a technique that replicates the cancer proteins that trigger the body's response to the disease and robotic technology that measures this response. The technology, called immuno-biomarkers, is based on work by John Robertson, a professor of surgery at the University of Nottingham's Faculty of Medicine and Health Sciences.

The company's test for lung cancer, called EarlyCDT-Lung will be launched in the US this month and in the UK early next year, Oncimmune said. It has obtained Medicare reimbursement for the test and will bill private insurers for it, it added.

Oncimmune licensed annexin biomarkers from Proteome Sciences last year for the test.

In a statement, Proteome Sciences said that Medicare's decision to cover the lung cancer test, which costs $475, "should make a substantial difference to the sales and the market size of the blood test."

The company will receive a royalty payment for each test sold.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.